Conferences
ASCO GU 2024: Enzalutamide Combination Treatment Suspension in Men with High-Risk Biochemically Recurrent Prostate Cancer: Outcomes from EMBARK
January 25, 2024
ASCO GU 2024: Underutilization of ADT Intensification for the Treatment of Men with mHSPC: A Systematic Review of Real-World Database Studies
January 25, 2024
ASCO GU 2024: Enfortumab Vedotin as Monotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results of Stage I of a Phase 2 Trial
January 25, 2024
PSMA PET and RLT 2024: Treatment Landscape in mCRPC
January 19, 2024
PSMA PET and RLT 2024: The Role of PSMA PET in CRPC Patients
January 19, 2024
PSMA PET and RLT 2024: Evaluation of the Primary Tumor with PSMA PET: Time Impact of the PRIMARY Trial
January 18, 2024
PSMA PET and RLT 2024: Do the Differences in PET Agents Matter?
January 18, 2024
PSMA PET and RLT 2024: PSMA Primer: The Background
January 18, 2024